Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Biomolex AS
AS
Active
Org 983453430
Melkeveien 39B, 0779
Oslo
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2001 · 25 years old
1 employees
biomolex.com
Monitor
Share
Norway
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Biomolex AS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (1)
HH
Håvard Hildeng Hauge
Chief Executive Officer
Chief Executive Officer
2002
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
EN
Eirik Næss-Ulseth
Chairman
Chairman
2021
HH
Håvard Hildeng Hauge
Board of Directors
Board of Directors
2021
Former (2)
JE
Jonas Einarsson
Board of Directors
Board of Directors
2017 – 2021
GV
Grete Vigen Rode
Board of Directors
Board of Directors
2017 – 2021
Shareholders
As of last annual report
Cerolu As — 21.45%
Skilling Systemer As — 17.66%
Inventron As — 15.07%
Sveinja Invest As — 7.51%
Integrated Detector Electronics As — 7.51%
Inven2 As — 3.3%
Thomas Langaard — 3.13%
Ja Consult As — 2.64%
Eirik Næss-Ulseth — 2.4%
Ivar Opsahl — 2.4%
Mia Fossbakk — 1.6%
Kimen As — 1.6%
Gillesen Overseas & Co As — 1.45%
Oslotech As — 1.32%
Lars Ingvar Viberger — 1.2%
90%
Shareholder
Type
Ownership
Votes
Since
Cerolu As
Company
21.45%
21.45%
2025
Skilling Systemer As
Company
17.66%
17.66%
2025
Inventron As
Company
15.07%
15.07%
2025
Sveinja Invest As
Company
7.51%
7.51%
2025
Integrated Detector Electronics As
Company
7.51%
7.51%
2025
Inven2 As
Company
3.3%
3.3%
2025
Thomas Langaard
Individual
3.13%
3.13%
2025
Ja Consult As
Company
2.64%
2.64%
2025
Eirik Næss-Ulseth
Individual
2.4%
2.4%
2025
Ivar Opsahl
Individual
2.4%
2.4%
2025
Mia Fossbakk
Individual
1.6%
1.6%
2025
Kimen As
Company
1.6%
1.6%
2025
Gillesen Overseas & Co As
Company
1.45%
1.45%
2025
Oslotech As
Company
1.32%
1.32%
2025
Lars Ingvar Viberger
Individual
1.2%
1.2%
2025
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Biomolex AS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network